Radiodynamic Therapy with Photosensitizers: Mini-Review of Experimental and Clinical Studies

• D.A. Tzerkovsky

  Laboratory of Photodynamic Therapy and Hyperthermia with Chemotherapy Group, N.N. Alexandrov National Cancer Center of Belarus, Lesnoy, Republic of Belarus

• A.N. Mazurenko

  Department of Centralized Dilution of Cytostatics, N.N. Alexandrov National Cancer Center of Belarus, Lesnoy, Republic of Belarus

• F.F. Borychevsky

  Neurosurgical Department, Minsk Regional Clinical Hospital, Lesnoy, Republic of Belarus

• D.V. Shashkouski

  Independent Researcher

Photodynamic Therapy (PDT) is a light-based method that uses photo-reactive molecules, such as different types of photosensitizers (PS), to destroy malignant tumors. As some authors testify, PS was shown to act as a radio-reactive molecule by enhancing generation of reactive oxygen species upon X-ray irradiation. The method of treatment, which is based on the combined use of PS and ionizing radiation, is called «Radiodynamic therapy» (RDT). The advantage of RDT over PDT is the X-ray’s penetrability through tissues, which will find many applications for treatment of deep malignant tumors. The authors of a number of research centers in Japan, Germany, Israel and Lithuania presented the experience of using RDT in experiments on tumor cell lines and animals with transplanted tumors. A clinical approbation of the method has been started in patients with unresectable forms of bladder and cervical cancer, with gliomas and other forms of malignant tumors. The data obtained in experiments on cultures of tumor cells and animals with transplanted tumors indicate a high antitumor efficacy of the RDT with various types of PS. This fact is confirmed by a statistically significant decrease in viable tumor cells with the combined use of RT and PS, as well as a pronounced inhibition of the growth of transplanted tumors compared with the control groups, including the group of radiation therapy in mono mode. The preliminary data obtained show good tolerability of the method in clinical oncology (no serious adverse reactions) and satisfactory antitumor efficacy (an increase in the frequency of objective responses and an increase in the % reduction in tumor volume, which made it possible to transfer them to a resectable state).

Tzerkovsky DA, Mazurenko AN, Kozlovsky DI, et al. Radiodynamic therapy with chlorine-based photosensitizer on Pliss lymphosarcoma solid tumor: in vivo experiment. J Analyt Oncol 2022; 11: 33-9. https://doi.org/10.30683/1927-7229.2022.11.05

Matsuyama Y, Nakamura T, Yoshida K, et al. Radiodynamic therapy with acridine orange local administration as a new treatment option for primary and secondary bone tumours. Bone Joint Res 2022; 11(10): 715-22. https://doi.org/10.1302/2046-3758.1110.BJR-2022-0105.R2

Yamamoto J, Ogura SI, Shimajiri S, et al. 5-Aminolevulinic acidinduced protoporphyrin IX with multi-dose ionizing irradiation enhances host antitumor response and strongly inhibits tumor growth in experimental glioma in vivo. Mol Med Rep 2015; 11(3): 1813-19. https://doi.org/10.3892/mmr.2014.2991

Schaffer M, Schaffer PM, Corti L, et al. Photofrin as a radiosensitizing agent for tumors: studies in comparison to other porphyrins, in an experimental in vivo model. J Photochem Photobiol 2002; 66(3): 157-64. https://doi.org/10.1016/S1011-1344(02)00237-3

Tzerkovsky DA, Protopovich YaL, Kozlovsky DI, et al. Antitumor efficiency of contact radiotherapy in combination with a chlorin-based photosensitizer in experiment. Biomed Photonics 2021; 10(2): 25-33. https://doi.org/10.24931/2413-9432-2021-10-2-25-33

Kulka U, Juzenas P, Moan J. Radiosensitization of tumours by porphyrins. Cancer Lett 2006; 235: 40-7. https://doi.org/10.1016/j.canlet.2005.03.041

Schaffer M, Schaffer PM, Jori G, et al. Radiation therapy combined with photofrin or 5-ALA: effect on Lewis sarcoma tumor lines implanted in mice. Preliminary results. Tumori 2002; 88: 407-10. https://doi.org/10.1177/030089160208800511

Кulka U, Schaffer M, Siefert A. Photofrin as a radiosensitizer in an in vitro cell survival assay. Cancer Lett 2003; 311: 98-103. https://doi.org/10.1016/j.bbrc.2003.09.170

Schaffer M, Balandin A, Ertl-Wagner B, et al. Does photofrin II combined with a radio-adaptive dose lead to a synergetic or additive effect after ionising irradiation in vitro? J Cancer Ther 2011; 2: 595-600. https://doi.org/10.4236/jct.2011.24079

Rutkovskienė L, Plėšnienė L, Sendiulienė D, et al. Sensitization of rat C6 glioma cells to ionizing radiation by porphyrins. Acta Medica Lituan 2011; 18(2): 56-62. https://doi.org/10.6001/actamedica.v18i2.1816

Benayoun L, Schaffer M, Bril R, et al. Рorfimer-sodium (Photofrin II) in combination with ionizing radiation inhibits tumor-initiating cell proliferation and improves glioblastoma treatment efficacy. Cancer Biol Ther 2013; 14(1): 64-74. https://doi.org/10.4161/cbt.22630

Takahashi J, Misawa M, Murakami M, et al. 5-aminolevulinic acid enhances cancer radiotherapy in a mouse tumor model. Springer Plus 2013; 2: 602-08. https://doi.org/10.1186/2193-1801-2-602

Di Pompo G, Kusuzaki K, Ponzetti M, et al. Radiodynamic therapy with acridine orange is an effective treatment for bone metastases. Biomedicines 2022; 10: 1904. https://doi.org/10.3390/biomedicines10081904

Schaffer M, Schaffer PM, Corti L. Photofrin II as an efficient radiosensitizing agent in an experimental tumor. Oncologie 2001; 24: 482-85. https://doi.org/10.1159/000055130

Yang DM, Cvetkovic D, Chen L, et al. Therapeutic effects of in-vivo radiodynamic therapy (RDT) for lung cancer treatment: a combination of 15MV photons and 5-aminolevulinic acid (5-ALA). Biomed Phys Eng Express 2022; 8(6): 1-15. https://doi.org/10.1088/2057-1976/ac9b5c

Bloznelytė-Plėnienė L, Stančius A. Gamadinaminis plitusių piktybinių navikų gydymas. Medicina 2002; 38(2): 186-89.

Shaffer M, Schaffer PM, Vogesser M, et al. Application of Photofrin II as a radiosensitizing agent in patients with bladder cancer – a report of two cases. Photochem Photobiol Sci 2002; 1(9): 686-89. https://doi.org/10.1039/b203732g

Schaffer M, Ertl-Wagner B, Schaffer PM, et al. Feasibility of photofrin II as a radiosensitizing agent in solid tumors – preliminary results. Onkologie 2006; 29: 514-19. https://doi.org/10.1159/000095979

Schaffer P, Batash R, Ertl-Wagner B, et al. Treatment of cervix carcinoma FIGO IIIb with Photofrin II as a radiosensitizer: a case report. Photochem Photobiol Sci 2019; 18: 1275-79. https://doi.org/10.1039/c8pp00576a

ClinicalTrials.gov Identifier: NCT04381806.

ClinicalTrials.gov Identifier: NCT05590689.

• PDF

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.